EUVIMEDEUVIMED entdecken
Open Access

Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D

Abigail L D Tadenev iD, Courtney L Hatton, Robert W Burgess iD

Journal of the Peripheral Nervous System · 2024

DOI: 10.1111/jns.12623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Abigail L D Tadenev und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Jackson Laboratory, Bar Harbor, Maine, USA. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Histone Deacetylase 6, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Charcot-Marie-Tooth Association, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhibition of HDAC6 has been proposed as a broadly applicable therapeutic strategy for Charcot–Marie–Tooth disease (CMT). Inhibition of HDAC6 increases the acetylation of proteins important in axonal trafficking, such as α‐tubulin and Miro, and has been shown to be efficacious in several preclinical studies using mouse models of CMT.

Aims

Here, we sought to expand on previous preclinical studies by testing the effect of genetic deletion of Hdac6 on mice carrying a humanized knockin allele of Gars1 , a model of CMT‐type 2D.

Methods

Gars1 ΔETAQ mice were bred to an Hdac6 knockout strain, and the resulting offspring were evaluated for clinically relevant outcomes.

Results

The genetic deletion of Hdac6 increased α‐tubulin acetylation in the sciatic nerves of both wild‐type and Gars1 ΔETAQ mice. However, when tested at 5 weeks of age, the Gars1 ΔETAQ mice lacking Hdac6 showed no changes in body weight, muscle atrophy, grip strength or endurance, sciatic motor nerve conduction velocity, compound muscle action potential amplitude, or peripheral nerve histopathology compared to Gars1 ΔETAQ mice with intact Hdac6 .

Interpretation

Our results differ from those of two previous studies that demonstrated the benefit of the HDAC6 inhibitor tubastatin A in mouse models of CMT2D. While we cannot fully explain the different outcomes, our results offer a counterexample to the benefit of inhibiting HDAC6 in CMT2D, suggesting additional research is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Charcot-Marie-Tooth DiseaseHistone Deacetylase 6Disease Models, AnimalAnimalsMiceHumansSciatic NerveMice, KnockoutGene DeletionMaleTubulinGlycine-tRNA LigaseNeural Conduction

Stichwörter der Autor:innen

Charcot–Marie–Tooth diseaseHDAC6 inhibitormouse modelpreclinical studytRNA synthetase

Substanzen

Histone Deacetylase 6Hdac6 protein, mouseTubulinGlycine-tRNA Ligase

Autor:innen und Institutionen

  • The Jackson Laboratory, Bar Harbor, Maine, USA.

ORCID-Profile: Abigail L D Tadenev, Robert W Burgess

Förderung

  • NIH HHS
  • Charcot-Marie-Tooth Association
  • NINDS NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health

Zitieren

APA

Tadenev, A. L. D., Hatton, C. L., & Burgess, R. W. (2024). Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12623

Vancouver

Tadenev ALD, Hatton CL, Burgess RW. Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12623

BibTeX
@article{Tadenev2024,
  author = {Tadenev, Abigail L D and Hatton, Courtney L and Burgess, Robert W},
  title = {Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  doi = {10.1111/jns.12623}
}
Kostenlos starten →